[{"orgOrder":0,"company":"Isoray","sponsor":"Viewpoint Molecular Targeting","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Merger","leadProduct":"VMT01","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Isoray","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Isoray \/ Isoray","highestDevelopmentStatusID":"7","companyTruncated":"Isoray \/ Isoray"}]

Find Clinical Drug Pipeline Developments & Deals by Isoray

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are entering Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions.

                          Brand Name : VMT01

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          February 06, 2023

                          Lead Product(s) : VMT01

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Viewpoint Molecular Targeting

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank